Enanta Pharmaceuticals(ENTA) - 2021 Q1 - Earnings Call Presentation

Financial Overview - Enanta Pharmaceuticals reported $122.5 million in total revenues for the fiscal year ended September 30, 2020[67] - The company held $400.4 million in cash, cash equivalents, and marketable securities as of March 31, 2021[14, 67] - Enanta anticipates receiving double-digit royalties on 50% of net sales of glecaprevir, a protease inhibitor, with Q1 2021 royalties at $20 million[66] Pipeline Development - Enanta is conducting a Phase 2b study (ARGON-2) for NASH and a Phase 1 study for a follow-on FXR agonist[7, 8] - Two Phase 1b studies are ongoing for HBV core inhibitor EDP-514, with a Phase 1 study for RNA destabilizer EDP-721 planned for mid-2021[9, 10] - EDP-938, an N-protein inhibitor for RSV, is in Phase 2b clinical trials, including RSVP, RSVPEDs, and RSVTx[3, 4, 5] Therapeutic Focus - Enanta is focused on developing oral treatments for viral infections and liver diseases, expanding beyond Hepatitis C (HCV) to include RSV, hMPV, COVID-19, NASH, and HBV[15] - For RSV, a Phase 2b study of EDP-938 in adult outpatients (RSVP) involves approximately 70 adults[27] - The company is also developing an RSV L-protein inhibitor with nanomolar potency against RSV-A and RSV-B[36] NASH Program - Enanta's FXR agonist EDP-305 is in a Phase 2b study (ARGON-2) with approximately 340 biopsy-proven NASH patients[62] - A 12-week internal interim analysis for the ARGON-2 Phase 2b study is planned for Q3 2021[62] - EDP-297, a follow-on FXR agonist, is in Phase 1 study, with data expected in mid-2021[63]